Predicting the time course of haemoglobin in children treated with erythropoietin for renal anaemia

British Journal of Clinical Pharmacology

Volumn 46, Issue 5, 1998, Pages 461-466

  Port, R E ^a   Ding, R W ^b,c   Fies, T ^b,d   Scharer K ^b,d  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c Division of Clinical Pharmacology   (Germany)

^d Division Nephrology   (Germany)

Author keywords

Haemoglobin; NONMEM; Pharmacodynamics; Population analysis

Indexed keywords

HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ADOLESCENT; ANALYTICAL ERROR; ANEMIA; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE CALCULATION; DOSE TIME EFFECT RELATION; FEMALE; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; MALE; PATIENT MONITORING; PHARMACODYNAMICS; PRIORITY JOURNAL; SCHOOL CHILD; STEADY STATE; SUBCUTANEOUS DRUG ADMINISTRATION;

ADOLESCENT; ANEMIA; BODY WEIGHT; CHILD; ERYTHROPOIETIN; FEMALE; HEMOGLOBINS; HUMANS; KIDNEY FAILURE; MALE; TIME FACTORS;

EID: 0031761911     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1998.00797.x     Document Type: Article

References (17)

1. Uehlinger DE, Gotch FA, Sheiner LB. A pharmacodynamic model of erythropoietin therapy for uremic anemia. Clin Pharmacol Ther 1992; 51: 76-89.
2. Van Damme-Lombaerts R, Broyer M, Businger J, Baldauf C, Stocker H. A study of recombinant human erythropoietin in the treatment of anemia of chronic renal failure in children on haemodialysis. Pediatr Nephrol 1994; 8: 338-342.
3. Mueller-Wiefel DE, Amon O. Erythropoietin treatment of anemia associated with chronic renal failure in children. Int J Pediatr Hematol Oncol 1995; 2: 87-95.
4. European Erythropoietin Symposium - Moving into the second decade of clinical experience in CRF (11-13 November 1994, Seville, Spain). Nephrol Dialysis Transplant 1995; 10(Suppl 2).
5. Brockmoeller J, Koechling J, Weber W, Looby M, Roots I, Neumayer HH. The pharmacokinetics and pharmacodynamics of recombinant human erythropoietin in haemodialysis patients. Br J Clin Pharmacol 1992; 34: 499-508.
6. Sheiner LB, Ludden TM. Population pharmacokinetics/dynamics. Ann Rev Pharmacol Toxicol 1992; 32: 185-209.
7. Port RE. Estimating individual pretreatment levels of a pharmacologic response variable. Population Approach Group in Europe. Sandwich UK, June 14-15th, 1996; volume of abstracts.
8. Efron B. Estimating the error rate of a prediction rule: Improvement on cross validation. J Am Stat Ass 1983; 78: 316-331.
9. Ette EI. Stability and performance of a population pharmacokinetic model. J Clin Pharmacol 1997; 37: 486-495.
10. Beal SL, Sheiner LB, eds NONMEM User's Guides. NONMEM Project Group, University of San Francisco, San Francisco/CA. 1992.
11. Sheiner LB, Rosenberg B, Marathe VV. Estimation of population characteristics of pharmacokinetic parameters from routine clinical data. J Pharmacokin Biopharm 1977; 5: 445-479.
12. Mueller-Wiefel DE, Sinn H, Gilli G, Schaerer K. Hemolysis and blood loss in children with chronic renal failure. Clin Nephrol 1977: 481-486.
13. Berlin NI, Berk PD. The biological life of the red cell. In The red blood cell (2nd edn), eds Surgenor D, Mar N. Vol. II. New York: Academic Press, 1975: 957-1019.
14. Weight LM, Byrne MJ, Jacobs P. Haemolytic effects of exercise. Clin Sci Colch 1991; 81: 147-152.
15. Eschbach JW, Kelly MR, Haley NR, Abels RI, Adamson JW. Treatment of the anaemia of progressive renal failure with recombinant human erythropoietin. New Engl J Med 1989; 321: 158-163.
16. Bommer J, Barth H-P, Zeier M, et al. Efficacy comparison of intravenous and subcutaneous recombinant human erythropoietin administration in hemodialysis patients. Contrib Nephrol 1991; 88: 136-143.
17. Macdougall IC. How to get the best out of r-HuEPO. Nephrol Dial Transplant. 1995: 10 (Suppl 2): 85-91.